Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | PCTP | Q9UKL6 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843456 | 0.88 | ADRA2B (0.58) | ALDH1A1CYP3A4SMN1; SMN2TDP1TSHR | |
| SCHEMBL5455334 | 0.85 | MAPT (0.71) | ALDH1A1GAALMNARXFP1POLB | |
| SCHEMBL16358817 | 0.84 | LMNA (0.71) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL28028309 | 0.82 | ALDH1A1 (0.94) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| SCHEMBL5453637 | 0.82 | PDE4A (0.71) | ALDH1A1TDP1LMNAPOLBMEN1 | |
| Sulfamethazine SCHEMBL151305 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL17256221 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL29918086 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL28447030 | 0.81 | ALDH1A1 (0.86) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| SCHEMBL12903578 | 0.81 | SMN1; SMN2 (0.76) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | OY JUVANTIA PHARMA LTD (FI) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | ADRB2, ADRB3, ADRB1 | ALDH1A1 1493/4885CYP3A4 2743/4885SMN1; SMN2 3331/4885 |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | ALDH1A1 816/4885CYP3A4 439/4885SMN1; SMN2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.